Therefore, we propose that a combination targeting both the TPL2/MEK/ERK pathway and the RAS/RAF/MEK/ERK pathway may potentially lead to new therapeutic intervention strategies of ADI prostate cancer (Figure S8). The gene discussed is MAP2K7; the disease is prostate cancer.